PL2632925T3 - N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA - Google Patents

N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA

Info

Publication number
PL2632925T3
PL2632925T3 PL11784783T PL11784783T PL2632925T3 PL 2632925 T3 PL2632925 T3 PL 2632925T3 PL 11784783 T PL11784783 T PL 11784783T PL 11784783 T PL11784783 T PL 11784783T PL 2632925 T3 PL2632925 T3 PL 2632925T3
Authority
PL
Poland
Prior art keywords
coa carboxylase
carboxylase inhibitors
lactam
acetyl
lactam acetyl
Prior art date
Application number
PL11784783T
Other languages
English (en)
Inventor
Scott William Bagley
Robert Lee Dow
David Andrew Griffith
Aaron Christopher Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PL2632925T3 publication Critical patent/PL2632925T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
PL11784783T 2010-10-29 2011-10-18 N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA PL2632925T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US201161531744P 2011-09-07 2011-09-07
EP11784783.0A EP2632925B1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
PCT/IB2011/054643 WO2012056372A1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (1)

Publication Number Publication Date
PL2632925T3 true PL2632925T3 (pl) 2015-10-30

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11784783T PL2632925T3 (pl) 2010-10-29 2011-10-18 N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA

Country Status (26)

Country Link
US (3) US8859773B2 (pl)
EP (2) EP2632925B1 (pl)
JP (2) JP5647356B2 (pl)
KR (2) KR20150006899A (pl)
CN (2) CN103189377B (pl)
AR (1) AR083578A1 (pl)
AU (1) AU2011322117B2 (pl)
BR (1) BR112013010310A2 (pl)
CA (1) CA2815169C (pl)
CY (1) CY1116405T1 (pl)
DK (1) DK2632925T3 (pl)
ES (1) ES2546465T3 (pl)
HK (1) HK1209733A1 (pl)
HU (1) HUE025078T2 (pl)
IL (1) IL225779A0 (pl)
MX (1) MX2013004733A (pl)
NZ (1) NZ609527A (pl)
PL (1) PL2632925T3 (pl)
PT (1) PT2632925E (pl)
RU (1) RU2540337C2 (pl)
SG (1) SG189883A1 (pl)
SI (1) SI2632925T1 (pl)
TW (3) TWI441823B (pl)
UY (1) UY33694A (pl)
WO (1) WO2012056372A1 (pl)
ZA (1) ZA201303882B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG189883A1 (en) * 2010-10-29 2013-06-28 Pfizer N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
EA028858B9 (ru) 2013-02-06 2018-06-29 Байер Кропсайенс Акциенгезельшафт Галогензамещенные производные пиразола в качестве средств борьбы с вредителями
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
CN105530940A (zh) 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN106749002A (zh) * 2015-02-12 2017-05-31 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
US10202351B2 (en) 2015-03-10 2019-02-12 Bayer Animal Health Gmbh Pyrazolyl derivatives as pest control agents
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN109963854B (zh) 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
SI3713942T1 (sl) 2017-11-21 2023-06-30 Pfizer Inc. Kristalizirana sol 2-amino-2(hidroksimetil)propan-1,3-diola 4-(4-(1-izopropil-7-okso-1,4,6,7-tetrahidrospiro(indazol-5,4'- piperidin)-1'-karbonil)-6-metoksipiridin-2-il)benzojske kisline
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
WO2021231191A1 (en) * 2020-05-12 2021-11-18 Merck Sharp & Dohme Corp. Factor xi activation inhibitors
EP4154880A4 (en) * 2020-05-21 2024-06-05 Shionogi & Co., Ltd MEDICINES FOR THE TREATMENT OF FATTY LIVER DISEASE
TW202246282A (zh) 2021-02-01 2022-12-01 美商西建公司 Mk2抑制劑、其合成及其中間體
TW202317104A (zh) * 2021-06-25 2023-05-01 美商賽迪拉治療股份有限公司 Tead抑制劑及其用途
KR20250037569A (ko) * 2022-07-29 2025-03-17 화이자 인코포레이티드 신규 acc 억제제
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (pl) * 1970-05-22 1974-07-02
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EA200300944A1 (ru) 2001-02-28 2004-04-29 Мерк Энд Ко., Инк. Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
JP2005504059A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール7−アザ[2.2.1]ビシクロヘプタン
BR0307874A (pt) 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
HRP20040716A2 (en) 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
HRP20090471T1 (hr) 2004-05-12 2009-10-31 Pfizer Products Inc. Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
RU2422446C2 (ru) 2005-07-19 2011-06-27 Мерк Шарп Энд Домэ Корп. Производные спирохроманона в качестве ингибиторов ацетил коэнзим а карбоксилазы (асс)
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP2463283B1 (en) 2006-04-20 2014-06-11 Pfizer Products Inc. Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
CN101541809A (zh) * 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) * 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
ES2545231T3 (es) * 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (en) * 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
JP5086480B2 (ja) 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
MX2012005429A (es) * 2009-11-10 2012-06-19 Pfizer Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa.
US20120225900A1 (en) * 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
ES2602111T3 (es) 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona
SG189883A1 (en) * 2010-10-29 2013-06-28 Pfizer N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Also Published As

Publication number Publication date
HK1209733A1 (en) 2016-04-08
US8993586B2 (en) 2015-03-31
JP2015057416A (ja) 2015-03-26
US20150025098A1 (en) 2015-01-22
EP2632925A1 (en) 2013-09-04
NZ609527A (en) 2014-03-28
WO2012056372A1 (en) 2012-05-03
CN104774205A (zh) 2015-07-15
MX2013004733A (es) 2013-07-02
TWI441823B (zh) 2014-06-21
CN103189377A (zh) 2013-07-03
US20120108619A1 (en) 2012-05-03
ES2546465T3 (es) 2015-09-23
EP2632925B1 (en) 2015-05-27
KR101529404B1 (ko) 2015-06-26
CA2815169A1 (en) 2012-05-03
PT2632925E (pt) 2015-09-01
HUE025078T2 (en) 2016-01-28
CN103189377B (zh) 2015-02-25
ZA201303882B (en) 2014-02-26
CA2815169C (en) 2015-10-06
US20150152109A1 (en) 2015-06-04
IL225779A0 (en) 2013-06-27
KR20150006899A (ko) 2015-01-19
RU2540337C2 (ru) 2015-02-10
DK2632925T3 (en) 2015-06-29
US8859773B2 (en) 2014-10-14
EP2952514A1 (en) 2015-12-09
TW201531472A (zh) 2015-08-16
AR083578A1 (es) 2013-03-06
SI2632925T1 (sl) 2015-07-31
AU2011322117B2 (en) 2015-01-22
KR20140014078A (ko) 2014-02-05
TW201302751A (zh) 2013-01-16
US9181252B2 (en) 2015-11-10
AU2011322117A1 (en) 2013-05-02
TWI507406B (zh) 2015-11-11
HK1186724A1 (en) 2014-03-21
JP2013542218A (ja) 2013-11-21
RU2013116924A (ru) 2014-12-10
BR112013010310A2 (pt) 2016-11-29
SG189883A1 (en) 2013-06-28
CY1116405T1 (el) 2017-02-08
TW201418256A (zh) 2014-05-16
JP5647356B2 (ja) 2014-12-24
UY33694A (es) 2012-05-31

Similar Documents

Publication Publication Date Title
ZA201303882B (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
PL2621493T3 (pl) N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
AP3283A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
AP3499A (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
HUE048834T2 (hu) Kináz inhibitorok
ZA201404156B (en) Kinase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
IL228103A0 (en) Amino-quinolines as kinase inhibitors
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201404157B (en) Kinase inhibitors
GB201018597D0 (en) Inhibitors
GB201120474D0 (en) Inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors
GB201010600D0 (en) Geodetic projections